|24.01||+0.0200||+0.08%||Vol 1.19M||1Y Perf 211.82%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||-0.02 -0.08%|
|Target Price||22.01||Analyst Rating||Moderate Buy 1.83|
|Potential %||-8.33||Finscreener Ranking||★+ 45.14|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 50.03|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 43.29|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||1.75B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||98.60||Earnings Date||3rd May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd May 2021|
|Estimated EPS Next Report||-0.05|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.97M|
|Avg. Monthly Volume||3.42M|
|Avg. Quarterly Volume||2.98M|
GenMark Diagnostics Inc. (NASDAQ: GNMK) stock closed at 24.01 per share at the end of the most recent trading day (a 0.08% change compared to the prior day closing price) with a volume of 1.24M shares and market capitalization of 1.75B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 618 people. GenMark Diagnostics Inc. CEO is Scott Mendel.
The one-year performance of GenMark Diagnostics Inc. stock is 211.82%, while year-to-date (YTD) performance is 64.45%. GNMK stock has a five-year performance of 347.11%. Its 52-week range is between 7.09 and 24.25, which gives GNMK stock a 52-week price range ratio of 98.60%
GenMark Diagnostics Inc. currently has a PE ratio of -82.60, a price-to-book (PB) ratio of 18.71, a price-to-sale (PS) ratio of 13.29, a price to cashflow ratio of 263.70, a PEG ratio of 2.32, a ROA of -10.81%, a ROC of -16.38% and a ROE of -34.71%. The company’s profit margin is -8.46%, its EBITDA margin is -6.70%, and its revenue ttm is $132.81 Million , which makes it $1.80 revenue per share.
Of the last four earnings reports from GenMark Diagnostics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. GenMark Diagnostics Inc.’s next earnings report date is 03rd May 2021.
The consensus rating of Wall Street analysts for GenMark Diagnostics Inc. is Moderate Buy (1.83), with a target price of $22.01, which is -8.33% compared to the current price. The earnings rating for GenMark Diagnostics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
GenMark Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
GenMark Diagnostics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.62, ATR14 : 1.05, CCI20 : 17.01, Chaikin Money Flow : -0.09, MACD : 1.68, Money Flow Index : 65.71, ROC : -0.17, RSI : 59.58, STOCH (14,3) : 44.74, STOCH RSI : 0.91, UO : 45.63, Williams %R : -55.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of GenMark Diagnostics Inc. in the last 12-months were: Alan Baer Maderazo (Option Excercise at a value of $1 497 571), Alan Baer Maderazo (Sold 213 578 shares of value $3 142 605 ), Brian Andrew Mitchell (Sold 84 324 shares of value $1 172 692 ), Christine Shaw (Sold 5 292 shares of value $85 824 ), Daryl J. Faulkner (Option Excercise at a value of $173 400), Eric Stier (Option Excercise at a value of $0), Eric Stier (Sold 99 870 shares of value $1 312 631 ), John Frederick Ek (Option Excercise at a value of $0), John Frederick Ek (Sold 106 449 shares of value $1 533 918 ), Michael Gleeson (Option Excercise at a value of $368 736), Michael Gleeson (Sold 69 250 shares of value $1 047 749 ), Michael John Harkins (Option Excercise at a value of $0), Michael John Harkins (Sold 27 104 shares of value $409 486 ), Sarah Hollis Winkler (Option Excercise at a value of $0), Sarah Hollis Winkler (Sold 26 480 shares of value $408 038 ), Scott Alexander O'Brien (Option Excercise at a value of $0), Scott Alexander O'Brien (Sold 50 217 shares of value $743 162 ), Scott Mendel (Option Excercise at a value of $0), Scott Mendel (Sold 362 046 shares of value $5 231 896 ), Tyler Jensen (Option Excercise at a value of $376 665), Tyler Jensen (Sold 94 648 shares of value $1 535 789 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.